# Ibio Inc (IBIO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/IBIO
## Company Profile
- Ticker: IBIO
- Exchange: AMEX
- Sector: Biopharma
- Location: United States
- Tags: Biologics
## Stock Data
- Close: 1.4 USD
- Market cap: 87434267.36 USD
- Last updated: 2026-08-05
## Business Overview
### AI-Enabled Antibody Discovery
iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties.
### IBIO-600
IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment.
### Cardiopulmonary Expansion
The pipeline also includes a bispecific antibody program for pulmonary hypertension associated with heart failure with preserved ejection fraction.
## Why The Stock Is Moving

As of Aug 5, 2026, IBIO closed down 4.11% at $1.40. No new same-company headline was identified in the current news window.

## Future Catalysts

- iBio has received Australian regulatory clearance to initiate a first-in-human Phase 1 study of IBIO-600.

## Drug Assets

- IBIO-600

## Recent News
- 2026-08-04 11:00 EST — [iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer](https://biopharmsignal.com/news/IBIO/ibio-strengthens-clinical-leadership-with-appointment-of-endocrinologist-molly-c-9c0b0cd2) — Source: Ibio Inc
- 2026-07-01 11:00 EST — [iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study](https://biopharmsignal.com/news/IBIO/ibio-reports-single-dose-of-ibio-610-achieved-near-complete-active-activin-e-inh-15c14063) — Source: Ibio Inc
- 2026-06-02 20:01 EST — [iBio to Participate in Upcoming Healthcare Investor Conferences](https://biopharmsignal.com/news/IBIO/ibio-to-participate-in-upcoming-healthcare-investor-conferences) — Source: Ibio Inc
- 2026-06-02 11:00 EST — [iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity](https://biopharmsignal.com/news/IBIO/ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity) — Source: Ibio Inc
- 2026-05-12 20:05 EST — [iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/IBIO/ibio-reports-q3-fiscal-year-2026-financial-results-and-provides-corporate-update) — Source: Ibio Inc